


Miglustat

Chemical Properties

CAS No. :	72599-27-0
Formula:	C ₁₀ H ₂₁ NO ₄
Molecular Weight:	219.28
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Miglustat (NB-DNJ) is an alkylated product of imino sugar deoxynojirimycin. It is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).
Targets(IC50)	Others, Transferase

Solubility Information

Solubility	DMSO: 130 mg/mL (592.85 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.5604 mL	22.8019 mL	45.6038 mL
5 mM	0.9121 mL	4.5604 mL	9.1208 mL
10 mM	0.456 mL	2.2802 mL	4.5604 mL
50 mM	0.0912 mL	0.456 mL	0.9121 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Abian, O., et al., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. *Mol Pharm*, 2011. 8(6): p. 2390-7.
- van Giersbergen, P.L. and J. Dingemans, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. *J Clin Pharmacol*, 2007. 47(10): p. 1277-82.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481